There is still uncertainty, but it is of a level where the cost of doing the research to reduce that uncertainty further, both in terms of health gain foregone from delaying general access and the direct cost of running the study, is less than the value of the uncertainty. It is just a bigger issue for rarer diseases, and that is why we have to [Inaudible—Editor].
On May 30th, 2016. See this statement in context.